VX-765: Selective Caspase-1 Inhibitor for Inflammation Research

Executive Summary: VX-765 is a potent, orally-available pro-drug inhibitor of caspase-1, enabling precise modulation of IL-1β and IL-18 in cell and animal models (APExBIO). It is metabolized in vivo to VRT-043198, the active compound. VX-765 does not affect TNFα, IL-6, IL-8, or IL-α, ensuring pathway selectivity (Exconde et al. 2023). The compound is widely used in studies of pyroptosis, rheumatoid arthritis, and HIV-associated T-cell death. Preclinical models confirm its efficacy in reducing inflammation and cytokine secretion. Proper storage and handling are essential for reproducible results.

Biological Rationale

The mammalian innate immune system uses pattern recognition receptors (PRRs) to detect pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) (Exconde et al. 2023). Upon activation, PRRs assemble inflammasomes that recruit and activate caspase-1. Caspase-1 (interleukin-1 converting enzyme, ICE) is a cysteine protease that cleaves pro-IL-1β and pro-IL-18 to their bioactive forms. These cytokines drive inflammation and pyroptosis, a lytic and inflammatory form of programmed cell death (see also: advanced mechanistic review). Dysregulated caspase-1 activity is implicated in autoinflammatory diseases, rheumatoid arthritis, and infectious pathologies including HIV-mediated T-cell depletion. Targeted inhibition of caspase-1 enables the study and therapeutic modulation of these critical processes.

Mechanism of Action of VX-765

VX-765 is an orally absorbed pro-drug. After administration, it is rapidly converted in vivo to its active metabolite, VRT-043198. VRT-043198 selectively inhibits caspase-1 enzymatic activity by binding to its catalytic site. This prevents the maturation of pro-IL-1β and pro-IL-18, reducing their secretion. Unlike broad-spectrum caspase inhibitors, VX-765 does not inhibit caspase-4/5/11 or affect the processing of TNFα, IL-6, IL-8, or IL-α (Exconde et al. 2023). This selectivity is critical for dissecting the role of canonical inflammasome signaling in inflammation and cell death (APExBIO).

Evidence & Benchmarks

• VX-765 blocks caspase-1-dependent processing of pro-IL-1β and pro-IL-18, reducing their release in vitro and in vivo (Exconde et al. 2023).
• In collagen-induced arthritis mouse models, VX-765 administration leads to significant reduction in joint inflammation and cytokine secretion (see APExBIO product page).
• Prevents CD4 T-cell pyroptotic death in HIV-infected lymphoid tissues in a dose-dependent manner (Exconde et al. 2023).
• In skin inflammation models, VX-765 reduces inflammatory markers without affecting levels of IL-6 or TNFα, confirming pathway specificity (related article).
• VX-765 demonstrates oral bioavailability and good solubility in DMSO (≥313 mg/mL) and ethanol (≥50.5 mg/mL with ultrasonic) (APExBIO).

This article extends prior work (VX-765: Selective Caspase-1 Inhibitor) by providing new quantitative performance data and highlighting best practices for reproducibility in complex disease models.

Applications, Limits & Misconceptions

Applications:

• Dissection of caspase-1 mediated inflammatory pathways in vitro and in vivo.
• Study of pyroptosis in macrophages following bacterial infection.
• Preclinical evaluation in autoimmune arthritis and skin inflammation models.
• Prevention of HIV-associated CD4 T-cell death in ex vivo lymphoid tissue cultures.
• Investigation of caspase-1 selective inhibition in translational inflammation research (see also: translational perspectives).

This article clarifies that, compared to previous reviews (Advancing Caspase-1 Inhibition), VX-765 offers enhanced selectivity for canonical inflammasome pathways, and provides updated solubility/storage information for experimental reproducibility.

Common Pitfalls or Misconceptions

• VX-765 does not inhibit caspase-4/5/11 (non-canonical inflammasome pathway); effects are limited to caspase-1-mediated events (Exconde et al. 2023).
• It does not reduce secretion of non-target cytokines (e.g., IL-6, TNFα, IL-8, IL-α); use alternative approaches for these pathways.
• VX-765 is a pro-drug; in vitro assays require conversion to VRT-043198 for direct enzymatic studies.
• Compound is insoluble in water; use DMSO or ethanol as solvents and ensure solutions are freshly prepared.
• Long-term storage of solutions reduces activity; store desiccated at -20°C and use within recommended time frames (APExBIO).

Workflow Integration & Parameters

For in vitro enzyme inhibition assays, dissolve VX-765 in DMSO at concentrations up to 313 mg/mL. For cell culture, dilute freshly in buffer (pH 7.5) with stabilizing additives. For in vivo studies, administer orally and allow in vivo conversion to VRT-043198. Solutions must be used promptly after preparation. Store powder desiccated at -20°C. For optimal reproducibility, reference established protocols and consider validated workflows such as those detailed in this application-driven guide, which this article updates by incorporating new solubility and selectivity data.

Conclusion & Outlook

VX-765 provides a highly selective, well-characterized tool for dissecting caspase-1-dependent inflammatory signaling. Its efficacy in both in vitro and in vivo models is supported by robust preclinical data. Key best practices include strict solvent selection, adherence to storage guidelines, and pathway-specific application. Ongoing studies continue to expand its utility in translational models of inflammation, autoimmunity, and infectious disease. For details on product acquisition and technical guidance, see the APExBIO VX-765 product page.